Skip to content
Open access

IL-17 in the prediction of the efficacy of biologic therapy for psoriasis

Sep 2026 · Meditsinskiy sovet = Medical Council · 0 citations · 27 references

Abstract

Introduction . Psoriasis is a common chronic immune-mediated inflammatory skin disease that significantly reduces patients’ quality of life. Modern treatment approaches, especially biologic therapy, demonstrate high efficacy; however, there is substantial interpatient variability in treatment response. Aim . To develop a prognostic model for assessing the risk of biologic therapy failure in patients with psoriasis. Materials and methods . The study included 52 patients with moderate-to-severe psoriasis receiving IL-17A inhibitor therapy. A comprehensive analysis of clinical parameters (PASI, BSA) and serum cytokine levels was performed. Treatment efficacy was assessed after 3 months according to a 50% reduction in the PASI score. Results. A therapeutic response was achieved in 75% of patients. The key predictor of treatment efficacy was the IL-17 level: patients with a positive response had significantly higher baseline levels of this cytokine. Based on the obtained data, a mathematical model for predicting the efficacy of biologic therapy was developed (p < 0.001; AUC = 0.820; 95% CI: 0.670–0.969) with a sensitivity of 69.2% and specificity of 82.1%. Discussion . A significant association was found between baseline IL-17 levels and treatment response. High IL-17 concentrations indicate an active Th17 response and predict a better treatment outcome. The developed model makes it possible to personalize treatment selection and minimize the risk of ineffective therapy. Conclusions . IL-17 levels are a significant predictor of the efficacy of biologic therapy in psoriasis. The developed prognostic model has high diagnostic value. A personalized approach to therapy selection based on biomarkers can optimize psoriasis treatment. The study results provide a basis for the development of personalized medicine in dermatology.  

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.